Hikal Ltd (HIKAL) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Hikal Ltd faced a challenging Q1 FY26 due to global overcapacity, pricing pressures, and demand volatility, particularly from Chinese competition.
- Consolidated revenue was 380 crores, and EBITDA was 25 crores.
- Pharmaceutical business revenue declined 11.7% YoY due to shipment deferments from key customers following an Official Action Indicated (OAI) status from the USFDA for their Bangalore facility.
- Crop protection business remained stable, driven by sporadic global demand, but faced pricing erosion.
- Successful GMP audits were conducted at the Bangalore API facility by regulatory authorities from Brazil, Japan (PMDA), and Visa.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.